Compare ASC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | ERAS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 6.3B |
| IPO Year | 2013 | 2021 |
| Metric | ASC | ERAS |
|---|---|---|
| Price | $18.67 | $16.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $17.00 | $14.25 |
| AVG Volume (30 Days) | 564.8K | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.31 | $1.53 |
| 52 Week High | $20.03 | $24.28 |
| Indicator | ASC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 38.62 |
| Support Level | $18.14 | $12.36 |
| Resistance Level | $18.91 | $19.13 |
| Average True Range (ATR) | 0.61 | 1.29 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 78.48 | 10.30 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.